Bristol Myers Squibb Teases Positive Phase 3 Data for Opdivo in NSCLC

November 8, 2021

Bristol Myers Squibb (BMS) unveiled positive interim results from its phase 3 CheckMate trial, showing that Opdivo (nivolumab) plus chemotherapy significantly improved event-free survival in patients with resectable IB-IIIA nonsmall-cell lung cancer (NSCLC).
Source: Drug Industry Daily

Posted in Drug Industry Daily